Boenning & Scattergood Maintains an 'Outperform' on MELA Sciences (MELA); Receives Positive FDA Advisory Panel Votes
Tweet Send to a Friend
Boenning & Scattergood maintains an 'Outperform' on MELA Sciences (NASDAQ: MELA), PT $10.
Boenning analyst says, "Yesterday, MELA Sciences presented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Boenning analyst says, "Yesterday, MELA Sciences presented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE